Whereas ALG-2 expression levels were reported to be unrelated to patient survival in breast, colon, and lung cancers [52], ALG-2 has been shown to be a potential prognostic biomarker for predicting clinical efficacy in certain types of cancers. Here, ALG2 is linked to lung cancer.